PhD Scientific Days

Poster Presentation: Oncology

P39: Examination of tumor infiltrating lymphocytes in breast cancer

Előadó neve

Szundi, Csilla

Előadó munkahelye

1. 2nd Department of Pathology

Előadó telefonszáma

06305861465

Előadó e-mail címe

szundi.csilla@gmail.com

Az előadás címe

Examination of tumor infiltrating lymphocytes in breast cancer

Szerző(k) neve és munkahelye

Csilla Szundi1, Laura Vízkeleti1,2, Janina Kulka1, Zsolt Fülöp3, Emőke Drágus3, Anna-Mária Tőkés1,4
1 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
2 MTA-SE-NAP, Brain Metastasis Research Group, Semmelweis University, Budapest, Hungary
3 University of Medicine and Pharmacy of Târgu Mureș, Marosvásárhely, Romania
4 MTA-SE Tumor Progression Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary

Szekció

Poster Presentation: Oncology

Data of the presenter

The name of the Doctoral School: Doctoral School of Pathological Sciences
The title of the Program:
Alterations of Cells, Fibres and Extracellular Matrix and Diagnostic Pathomorphological Studies in the Course of Heart and Vascular Diseases and in Certain Tumours. Experimental and Diagnostic Pathomorphological Studies
The name of the Supervisor: Anna-Mária Tőkés
The E-mail address of the presenter: szundi.csilla@gmail.com

Text of the abstract

Introduction: Breast cancer (BC) is one of the most common disease in women all over the world. Several studies consider that the prognostic value of tumor infiltrating lymphocytes (TIL) in TNBC could be considered Level I evidence, and data suggest that high levels of TILs are also associated with better outcomes in HER2 disease.
Aims: To analyse stromal TIL on Haematoxylin and Eosin (HE) stained slides of surgically resected BC tissues and to correlate TIL ratios with subtype and patients’ follow-up data.
Methods: Our cohort consisted of 78 LUMA, 94 LUMB1, 48 LUMB2, 49 HER2+ and 52 TNBC breast carcinomas diagnosed between 2000 and 2009 with known follow-up data. Surrogate molecular subtypes were defined based on the 2011 St. Gallen recommendations. Stromal TIL was evaluated on HE stained slides at 200x magnification based on the recommendations of the International TILs working group (2014). Distant metastasis free survival (DMFS) was defined as the time elapsed between the first pathological diagnosis of the tumor and the detection of the first distant metastasis. Statistical analysis was performed with SPSS Statistics for Windows, Version 22.0.
Results: Reliable follow-up data were available in 307 cases. During the analysed period we have detected distant metastases in 80/307 (26,1%) cases. Significantly higher TIL ratio was observed in HR-negative BC subgroups compared to HR-positive groups (p<0.001), and high TIL ratio was also significantly associated with DM formation (p=0.011). Fifty of the 225 cases (22.2%) without metastasis presented high (≥10%) TIL content. In metastatic group this was 12.5%.
Conclusions: TIL is a promising prognostic marker in at least HR-negative BC. The cut off value discriminating high and low TIL ratio is still questionable and needs defining. An other question to be solved is the role of the different immune cell types in correlation with tumor progression.

Azonosító

P39

Kind

Szabad

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

1207

PhD Scientific Days 2017

Budapest, 11-12 April 2017